HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. (Q45387477)
Jump to navigation
Jump to search
scientific article published on 10 May 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. |
scientific article published on 10 May 2011 |
Statements
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab (English)
Alison Stopeck
Hannah Linden
David Solit
Sarat Chandarlapaty
Neal Rosen
Maura Dickler
Steven Sugarman
Sujata Patil
Alison L Hannah